Veracyte | VCYT

Stock Price
29.71
Daily Change
-1.50 -4.81%
Monthly
-1.79%
Yearly
39.03%
Q2 Forecast
29.17


Peers Price Chg Day Year Date
Agilent 106.83 -1.81 -1.66% -26.52% May/09
Arrowhead Research 13.03 -0.22 -1.66% -40.99% May/09
Bruker 37.52 -2.99 -7.38% -50.44% May/09
Exact Sciences 51.63 -1.43 -2.70% -3.51% May/09
Illumina 75.76 -3.82 -4.80% -31.52% May/09
Ligand Pharmaceuticals 104.48 1.97 1.92% 19.71% May/09
Laboratory Of America 245.75 -3.27 -1.31% 19.22% May/09
Myriad Genetics 3.89 -0.14 -3.47% -84.73% May/09
Roche Holding 257.60 -2.30 -0.88% 14.44% May/09
Sonic Healthcare 26.80 0.28 1.06% 0.15% May/09
Siemens 214.05 0.85 0.40% 13.61% May/09
Thermo Fisher Scientific 402.60 -7.99 -1.95% -32.14% May/09
Veracyte 29.71 -1.50 -4.81% 39.03% May/09
Waters 344.08 -6.87 -1.96% 2.35% May/09

Indexes Price Day Year Date
USND 17929 0.78 0.004% 9.72% May/09
US2000 2023 -3.34 -0.16% -1.58% May/09

Veracyte traded at $29.71 this Friday May 9th, decreasing $1.50 or 4.81 percent since the previous trading session. Looking back, over the last four weeks, Veracyte lost 1.79 percent. Over the last 12 months, its price rose by 39.03 percent. Looking ahead, we forecast Veracyte to be priced at 29.17 by the end of this quarter and at 27.61 in one year, according to Trading Economics global macro models projections and analysts expectations.

Veracyte, Inc. is a genomic diagnostics company. The Company, through its scientific platform, which utilizes ribonucleic acid (RNA), whole-transcriptome sequencing combined with machine learning, produces genomic tests. It provides various genomic tests, including Afirma Genomic Sequencing Classifier (GSC), Percepta Bronchial Genomic Classifier, Envisia Genomic Classifier and Afirma Xpression Atlas. It provides GSC tests for thyroid cancer. It provides Percepta Bronchial Genomic Classifier tests for lung cancer. It provides Envisia Genomic Classifier tests for idiopathic pulmonary fibrosis (IPF). Its Afirma Xpression Atlas provides information on gene alterations associated with thyroid cancer, enabling physicians to tailor surgical and treatment decisions at time of diagnosis.